Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 randomized double-blind placebo-controlled study of AMG 531 in pediatric chronic immune thrombocytopenic purpura
2007-003569-42Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Romiplostim with Placebo (2 arms). Primary endpoint: Incidence of adverse events and antibody formation. Started Aug 2007; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2007-003569-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003569-42.